Functional roles of microRNAs in pancreatic islet autoimmunity: what do we know and where do we target?

Type 1 diabetes (T1D) results from a destructive dialog between stressed pancreatic beta-cells and immune system. While current disease-modifying approaches targeting these processes are being developed and tested, microRNAs have emerged as a molecular interface connecting both sides of islet autoimmunity.

Specific miRNAs orchestrate beta-cell stress adaptation, immune activation, and intercellular communication, thus shaping disease trajectory and progression across stages. Recent discoveries identified distinct miRNA networks as ER-stress modulators and/or immune amplifiers and key regulators of beta-cell fate and circulating signals of ongoing inflammation.

The clinical translation of these insights remains hindered by limited access to human tissues, inconsistent candidate validation, and lack of delivery systems capable of targeting pancreatic beta-cells. Bridging mechanistic understanding with advanced delivery systems may transform miRNAs both as biomarkers and active therapeutic agents, opening a path toward precision interventions in T1D.